Viatris Inc.
VTRS
Hisse Senetlerindeki Sıralama
#1095
Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its... Viatris Inc. operates as a global pharmaceutical and healthcare enterprise. Its business is structured across four primary geographic divisions: Developed Markets, Greater China, JANZ (Japan, Australia, New Zealand), and Emerging Markets. The company offers a comprehensive range of pharmaceutical products, encompassing branded prescription medications, generic and complex generic drugs, biosimilar treatments, and active pharmaceutical ingredients (APIs). These offerings target diverse therapeutic areas, addressing both noncommunicable and infectious diseases. Its biosimilars specifically focus on critical conditions in oncology, immunology, endocrinology, ophthalmology, and dermatology. Furthermore, Viatris's APIs are utilized across numerous drug categories, including antibacterials, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitors. Beyond manufacturing medicines, Viatris supports patient well-being through additional services such as diagnostic clinics, educational seminars, and digital tools designed to assist with health management. Products are made available in various forms, including oral solids, injectable solutions, complex dosage formulations, and raw APIs. Viatris distributes these to a broad clientele globally, including retail pharmacies, wholesalers, government bodies, insurance providers, and institutional healthcare facilities. The distribution network involves pharmaceutical wholesalers, retail and institutional pharmacies, mail-order and e-commerce platforms, and specialty pharmacies. The company's extensive portfolio includes prominent brands like Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, Yupelri, Norvasc, Viagra, AMITIZA, Lipacreon, Effexor, Celebrex, and ARV. Its biosimilar franchises feature products such as Fulphila, Ogivri, Hulio, and SEMGLEE. Viatris Inc. also fosters innovation through strategic collaborations and licensing agreements with partners including Revance Therapeutics, Inc., Momenta Pharmaceuticals, Inc., Theravance Biopharma, Inc., Biocon Ltd., and Fujifilm Kyowa Kirin Biologics Co. Ltd. Founded in 1961, Viatris Inc. maintains its corporate headquarters in Canonsburg, Pennsylvania.
Hisse Fiyatı
$18.55
Son senkronizasyon: 2026-10-16
Piyasa Değeri
$21.31B
Değişim (1 gün)
1.81%
Değişim (1 yıl)
82.40%
Ülke
US
Ticaret Viatris Inc. (VTRS)
Kategori
Healthcare
Viatris Inc. (VTRS) için Faaliyet Marjı
October 2026 itibarıyla Faaliyet Marjı TTM: -0.59%
Viatris Inc. şirketinin en son finansal raporlarına ve hisse fiyatına göre, mevcut faaliyet marjı (TTM) -0.59%'dir. 2023 yılı sonunda şirketin faaliyet marjı 4.97% idi.
Viatris Inc. için 2004 ile 2026 arasındaki Faaliyet Marjı geçmişi
Her yıl sonunda Faaliyet Marjı
| Yıl | Faaliyet Marjı | Değiştir |
|---|---|---|
| 2026 (TTM) | -0.59% | -942.86% |
| 2024 | 0.07% | -98.59% |
| 2023 | 4.97% | -49.95% |
| 2022 | 9.93% | -5,326.32% |
| 2021 | -0.19% | -89.20% |
| 2020 | -1.76% | -128.30% |
| 2019 | 6.22% | -21.46% |
| 2018 | 7.92% | -34.38% |
| 2017 | 12.07% | 91.28% |
| 2016 | 6.31% | -59.26% |
| 2015 | 15.49% | -11.59% |
| 2014 | 17.52% | 6.63% |
| 2013 | 16.43% | 0.67% |
| 2012 | 16.32% | -0.49% |
| 2011 | 16.40% | 23.87% |
| 2010 | 13.24% | 28.79% |
| 2009 | 10.28% | 77.24% |
| 2008 | 5.80% | -54.69% |
| 2007 | 12.80% | -44.01% |
| 2006 | 22.86% | -5.18% |
| 2005 | 24.11% | -33.03% |
| 2004 | 36.00% | 0.00% |
Benzer şirketler veya rakipler için Faaliyet Marjı
| Şirket | Faaliyet Marjı | Faaliyet Marjı Farkı | Ülke |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -138.86% |
IN
|
Bir şirketin Faaliyet Marjı'ı nedir?
Faaliyet Marjı, bir şirketin kârlılığını değerlendirmek için temel bir göstergedir. Daha yüksek Faaliyet Marjı değerleri genellikle daha iyidir çünkü bir şirketin ürün veya hizmetlerini üretim maliyetlerinden çok daha yüksek bir fiyata satabildiğini gösterir. Faaliyet Marjı, şirketin kârının gelirine bölünmesiyle hesaplanır.